BaxDuo-Baltic
Research type
Research Study
Full title
A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure
IRAS ID
1012864
Contact name
Hannah Pollard
Contact email
Sponsor organisation
AstraZeneca AB
Research summary
In this trial, researchers are looking into how well an experimental drug called baxdrostat works when combined with another drug called dapagliflozin, and how safe the combination of the two drugs is. These drugs are designed to improve Chronic Kidney Disease (CKD) by protecting kidney function in different ways. Dapagliflozin, also known as Farxiga or Forxiga, is a type of medication called an SGLT2 inhibitor (SGLT2i). Dapagliflozin is already approved to help people with CKD, heart failure, or type 2 diabetes. It helps the body remove sugar from the blood through the urine and helps slow the worsening of kidney function in CKD. But, dapagliflozin cannot completely prevent the worsening of CKD in all people.
Baxdrostat is an experimental drug designed to stop extra fluid and waste from building up in the body and to reduce high blood pressure. High blood pressure, also called hypertension, is one of the most common causes of CKD.
Researchers think that combining baxdrostat and dapagliflozin could help improve CKD and high blood pressure more than either drug alone, while also reducing the risk of hyperkalaemia. Hyperkalaemia is a common medical problem in people with CKD. Hyperkalaemia means a person has high levels of potassium in their blood, which can cause tiredness and muscle weakness, or stiffness. In serious cases, it can cause heart problems like irregular heartbeats.
In this trial, the researchers want to learn if taking baxdrostat and dapagliflozin together could help participants with CKD and high blood pressure more than taking baxdrostat and a placebo together. The placebo will look like dapagliflozin but will not have any active medicine in it. Researchers use a placebo to make sure any of the effects they see in participants who take a treatment are actually caused by that treatment.REC name
London - Central Research Ethics Committee
REC reference
25/LO/0725
Date of REC Opinion
1 Dec 2025
REC opinion
Further Information Favourable Opinion